Research programme: monoclonal antibody immunoconjugates - Valor Biotherapeutics

Drug Profile

Research programme: monoclonal antibody immunoconjugates - Valor Biotherapeutics

Alternative Names: CmAbs; IGN 001; IGN 003; mAb-IFN fusion protein therapeutics - Valor Biotherapeutics; mAb-IFN therapeutics - ImmunGene/Valor Biotherapeutics; Monoclonal antibody fusion proteins - ImmunGene/Caliber Biotherapeutics/Valor Biotherapeutics

Latest Information Update: 12 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ImmunGene
  • Developer Valor Biotherapeutics
  • Class Immunoconjugates; Monoclonal antibodies; Proteins
  • Mechanism of Action Apoptosis stimulants; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Multiple myeloma
  • Research Cancer

Most Recent Events

  • 02 May 2017 Early research development for Cancer is ongoing in USA, before May 2017
  • 02 May 2017 ImmunGene acquires IGN 001 and IGN 003 from Valor Biotherapeutics
  • 02 May 2017 Preclinical trials in Breast cancer in USA (Parenteral), before May 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top